Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients

European Journal of Cancer

Volumn 51, Issue 10, 2015, Pages 1293-1302

  Powles, Thomas ^a   Bracarda, Sergio ^b   Chen, Mei ^c   Norry, Elliot ^c   Compton, Natalie ^d   Heise, Mark ^c   Hutson, Thomas ^e   Harter, Philipp ^f   Carpenter, Christopher ^c   Pandite, Lini ^c   Kaplowitz, Neil ^g  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f KLINIKEN ESSEN MITTE   (Germany)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

ALT elevation; Drug induced liver injury; Hepatotoxicity; Hyperbilirubinemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PAZOPANIB; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG SAFETY; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INCIDENCE; KIDNEY CARCINOMA; META ANALYSIS; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK FACTOR; SIDE EFFECT; SOFT TISSUE SARCOMA; SYSTEMATIC REVIEW; TOXIC HEPATITIS; ADOLESCENT; ADULT; AGED; DRUG EFFECTS; ENZYMOLOGY; FEMALE; LIVER; MALE; METABOLISM; MIDDLE AGED; NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; NEOPLASMS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; YOUNG ADULT;

EID: 84930667814     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.03.019     Document Type: Review

References (24)

1. GlaxoSmithKline. Votrient (pazopanib) tablets prescribing information. GlaxoSmithKline: Research Triangle Park, NC. Revised June 2014. Available at: < http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022465s-010S-012lbl.pdf >; [accessed 27.10.14].
2. R.R. Shah, J. Morganroth, and D.R. Shah Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives Drug Saf 36 7 2013 491 503
3. D. Petrucci, C. Hu, K. French, L. Webster, K. Skordos, and R. Brown Preclinical investigations into potential mechanisms of pazopanib-induced hepatotoxicity in patients Toxicol Sci 126 Suppl. 1 2012 Abstract 2262
4. S.J. Klempner, T.K. Choueiri, E. Yee, L.A. Doyle, D. Schuppan, and M.B. Atkins Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients J Clin Oncol 30 27 2012 e264 e268
5. C.F. Spraggs, L.R. Budde, L.P. Briley, N. Bing, C.J. Cox, and K.S. King HLA-DQA1∗02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer J Clin Oncol 29 6 2011 667 673
6. T.E. Hutson, I.D. Davis, J.P. Machiels, P.L. De Souza, S. Rottey, and B.F. Hong Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma J Clin Oncol 28 3 2010 475 480
7. R.J. Motzer, T.E. Hutson, D. Cella, J. Reeves, R. Hawkins, and J. Guo Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 8 2013 722 731
8. C.N. Sternberg, I.D. Davis, J. Mardiak, C. Szczylik, E. Lee, and J. Wagstaff Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 6 2010 1061 1068
9. R.J. Motzer, T. Johnson, T.K. Choueiri, K.C. Deen, Z. Xue, and L.N. Pandite Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms Ann Oncol 24 11 2013 2927 2928
10. C.F. Xu, B.H. Reck, Z. Xue, L. Huang, K.L. Baker, and M. Chen Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism Br J Cancer 102 9 2010 1371 1377
11. G.P. Aithal, P.B. Watkins, R.J. Andrade, D. Larrey, M. Molokhia, and H. Takikawa Case definition and phenotype standardization in drug-induced liver injury Clin Pharmacol Ther 89 6 2011 806 815
12. R.J. Andrade, M.I. Lucena, M.C. Fernandez, G. Pelaez, K. Pachkoria, and E. Garcia-Ruiz Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period Gastroenterology 129 2 2005 512 521
13. H.J. Zimmerman Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver 2nd ed. 1999 Lippincott Williams & Wilkins Philadelphia, PA
14. S. Sleijfer, I. Ray-Coquard, Z. Papai, A. Le Cesne, M. Scurr, and P. Schoffski Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) J Clin Oncol 27 19 2009 3126 3132
15. W.T. van der Graaf, J.Y. Blay, S.P. Chawla, D.W. Kim, B. Bui-Nguyen, and P.G. Casali Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 379 9829 2012 1879 1886
16. A. du Bois, A. Floquet, J.-W. Kim, J. Rau, J.M. del Campo, and M. Friedlander Incorporation of pazopanib in maintenance therapy of ovarian cancer J Clin Oncol 32 30 2014 3374 3382
17. US Food and Drug Administration. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. July 2009. Available at: < http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf >; [accessed 29.10.14].
18. R.M. Green, and S. Flamm AGA technical review on the evaluation of liver chemistry tests Gastroenterology 123 4 2002 1367 1384
19. G. Danan, and C. Benichou Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries J Clin Epidemiol 46 11 1993 1323 1330
20. R.J. Fontana, L.B. Seeff, R.J. Andrade, E. Bjornsson, C.P. Day, and J. Serrano Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop Hepatology 52 2 2010 730 742
21. R.J. Fontana, P.B. Watkins, H.L. Bonkovsky, N. Chalasani, T. Davern, and J. Serrano Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct Drug Saf 32 1 2009 55 68
22. Kaplowitz N, DeLeve LD. Drug-induced liver disease. 3rd ed. Waltham, MA: Academic Press (Elsevier); 2013. p. 3-14.
23. B.I. Rini, D.P. Cohen, D.R. Lu, I. Chen, S. Hariharan, and M.E. Gore Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 9 2011 763 773
24. Wang X, Xue Z, Carpenter C, Harter P, King K, Stinnett S, et al. Genome-wide association study (GWAS) for transaminase elevations in pazopanib-treated patients. Poster (abstract 3479S) presented at: ASHG 2014 Annual Meeting; October 18-22, 2014; San Diego, CA.